BIA
FLNA

Bell Investment Advisors’s Filana Therapeutics FLNA Stock Holding History

Bell Investment Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-14
Closed -$414 – 1973
2022
Q4 		$414 Buy
+14
New +$503 ﹤0.01% 1902

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCM
Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bell Investment Advisors's FLNA Position: Q1 2023 in Review

Bell Investment Advisors sold out of Filana Therapeutics (FLNA) in Q1 2023, closing a stake of 14 shares — an estimated $414 sold.

Bell Investment Advisors first reported a position in FLNA in Q4 2022 and held it in 1 quarter. The position peaked at $414 in Q4 2022. 145 funds tracked by Wall St. Rank hold FLNA as of Q1 2023.

  • Bell Investment Advisors reported no remaining Filana Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Bell Investment Advisors sold 14 Filana Therapeutics shares in Q1 2023, an estimated $414.
  • Bell Investment Advisors first reported a position in Filana Therapeutics in Q4 2022 and held it in 1 quarter.
  • Bell Investment Advisors's Filana Therapeutics position peaked at $414 in Q4 2022.
  • 145 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2023.

Based on Bell Investment Advisors's 13F filing for Q1 2023, filed 10 May 2023.